Encouraging Results From a Pilot Study Testing the Bionic Pancreas in Cystic Fibrosis Related Diabetes Published in the Journal of Cystic Fibrosis.

Boston, MA-December 3,2019- Beta Bionics, Inc. — a medical technology company developing and aiming to commercialize the world`s first fully automated bionic pancreas today announced that its bionic pancreas glucose control algorithms that use lifelong autonomous learning were deployed in a pilot study comparing usual care with automated insulin-only and bihormonal (insulin and glucagon) delivery in three patients with cystic fibrosis related diabetes (CFRD). Results of the study were published in the Journal of Cystic Fibrosis (J.S. Sherwood, R.Z. Jafri, C.A. Balliro, et a\., Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: A pilot study, Journal of Cystic Fibrosis, https://doi.Org/10.1016/j.jcf.2019.08.002).

Beta Bionics, Inc. announced that its bionic pancreas glucose control algorithms that use lifelong autonomous learning were deployed in a pilot study comparing usual care with automated insulin-only and bihormonal (insulin and glucagon) delivery in three patients with cystic fibrosis-related diabetes (CFRD).